Serum marker PAP was used to monitor and assess progression of
prostate cancer until the introduction of
prostate specific antigen (PSA), which has now largely displaced it. Subsequent work, suggested that it has a role in
prognosticating intermediate and high-risk prostate cancer, and led to renewed interest in it as a
biomarker.
Immunohistochemistry PAP
immunohistochemical staining is often used with PSA (staining), by
pathologists, to help distinguish poorly differentiated
carcinomas. For example, poorly differentiated prostate adenocarcinoma (
prostate cancer) and
urothelial carcinoma (
bladder cancer) may appear similar under the
microscope, but PAP and
PSA staining can help differentiate them; prostate adenocarcinoma often stains with PSA and/or PAP, while urothelial carcinoma does not. ==HIV==